Nephrogenic systemic fibrosis is a severe disabling disease that can follow gadolinium-based contrast exposure. In this study we analyzed the clinical and laboratory records of patients with nephrogenic systemic fibrosis who had a history of exposure to gadolinium-based contrast media and identified their cardiac and vascular events. At autopsy, we found that the heart, blood vessels, and skin of three patients who died of cardiac and/or vascular complications had appreciable amounts of gadolinium, iron, and aluminum as measured by inductively coupled plasma-mass spectrometry and confirmed by x-ray fluorescence. Of the 32 patients with nephrogenic systemic fibrosis studied, 10 died at a median of 112 days after diagnosis. Cardiovascular events contributed to the mortality of 9 patients and included congestive heart failure, recurrent arrhythmias, hypotension, stroke, limb ischemia, posterior ischemic optic neuropathy and sudden death. Our results show that increased cardiac and vascular complications along with short survival in nephrogenic systemic fibrosis are associated with metal accumulation in the heart, blood vessels, and skin of these patients. KEYWORDS: gadolinium; iron; aluminum; fibrosis; mortality; cardiovascular Nephrogenic systemic fibrosis (NSF) is a systemic illness comprised of fibrosis 1 and systemic inflammation, 2, 3 and is reported almost exclusively in patients with renal insufficiency who are exposed to gadolinium-based contrast material. 4 On the basis of the demonstration of gadolinium in the skin of NSF patients, 5 the USFDA recently issued a black box warning about the risk of NSF upon gadoliniumbased contrast material exposure. Demonstration of significant quantities of insoluble gadolinium in the skin of NSF patients, months after gadolinium-based contrast material exposure and after extensive tissue processing, suggests that gadolinium might have undergone transmetallation in vivo. Supporting the importance of transmetallation, all NSF cases reported thus far have been associated with linear magnetic resonance contrast agents 4, [6] [7] [8] that have inferior thermodynamic stability 9,10 and a kinetic or conditional stability that favors transmetallation.
Only limited data exist on the clinical course and prognosis in NSF. 2, 6 Gadolinium-based contrast material exposure induces pro-inflammatory effects and iron mobilization. 6 Iron mobilization, in addition to being an indicator of transmetallation, may increase the risk of cardiovascular complications. [11] [12] [13] To study this hypothesis further, in the present study we evaluated the clinical history of all NSF patients who died at a single tertiary-care institution, the University of Arkansas for Medical Sciences (UAMS). In three patients for whom an autopsy was obtained, we quantified metals including gadolinium, iron, and aluminum found in various organs sampled including the heart as well as the arteries.
(37-84) years; of those, seven were female. Six patients had diabetes mellitus prior to the diagnosis of NSF, whereas one patient subsequently developed new-onset diabetes mellitus. None of the patients had been treated with aluminum-based phosphate binders. All patients had been exposed to gadodiamide at variable doses (15 ml to angiographic doses) and frequency before the development of NSF. Seven patients had end-stage renal disease at the time of gadolinium exposure and three patients developed acute worsening of kidney function and became dialysis dependent after gadolinium exposure.
Clinical conditions associated with death
Cardiovascular disease contributed to mortality in the majority of UAMS patients (n ¼ 9) and in one patient at the University of Colorado Health Sciences Center (UCHSC). Sepsis (n ¼ 5) and discontinuation of dialysis (n ¼ 1) contributed to mortality in some patients. Cardiac and vascular causes that contributed to the demise of NSF patients include congestive heart failure (CHF; n ¼ 3), hypotension (n ¼ 4), cardiac arrhythmias (n ¼ 2), myocardial ischemia (n ¼ 1), sudden death (n ¼ 1), stroke (n ¼ 1), and limb ischemia (n ¼ 1). One patient developed blindness secondary to posterior ischemic optic neuropathy. The patient from UCHSC also died of CHF and a persistent cardiac arrhythmia (Table 1) . Dialysis was discontinued prior to death in one patient because of multiple comorbidities related to restricted mobility, pain, and an ensuing poor quality of life.
Histopathology data and quantification of metals on an autopsy specimen A complete autopsy was performed on two NSF patients who died at UAMS. The first patient developed NSF four days after gadolinium exposure and died one month later with new-onset limb ischemia and gangrene, myocardial ischemia, and hypotension ( Figure 1 ) aluminum. In the second patient, NSF was diagnosed two months after exposure to gadolinium contrast; this patient died nine months later following sudden onset monocular blindness (posterior ischemic optic neuropathy), stroke, and hypotension. A histopathologic examination of tissues sampled at autopsy revealed diffuse mural calcification of arterial vasculature including the temporal artery and branches to multiple viscera, extensive scleral calcification, diffuse myocardial fibrosis, and central venous congestion of the liver. On quantitative analysis, significant quantities of gadolinium could be detected in the skin (255 mg g ). An analysis of the heart revealed increased quantities of iron (62.9 mg g À1 ) and aluminum (29.9 mg g
À1
). An immunohistochemical stain of a coronary artery showed proliferation of CD34-positive spindle cells; the same artery also contained a significant quantity of gadolinium and iron ( Figure 2) .
Similarly, in the patient who died of CHF and recurrent arrhythmia at UCHSC, significant quantities of gadolinium could be detected in his heart (two sample areas; 442 and 426 mg g
) and soft tissue (skin and underlying muscle of the right arm; 100.4 mg g À1 ). A histopathology of the heart revealed significant fibrosis (Figure 3) . These data were then compared with data from three control skin biopsies obtained during re-excision of basal cell skin cancer and three renal arteries obtained from deceased potential kidney donors for metal content using inductively coupled plasma-mass spectrometry (ICP-MS) ( Table 2 ). As shown, significantly higher iron accumulation was evident in the NSF biopsies compared with controls. Although statistically insignificant, aluminum content was also higher in the NSF skin biopsies and aorta than in controls. The vascular iron content in the blood vessels of NSF patients was also higher than the reported iron content (9.4 mg g
) in normal blood vessels. 14 Because prior reports of gadolinium deposition in the affected tissue of NSF were confined only to the skin and soft tissue, an independent means to confirm gadolinium deposition within cardiac tissue was sought. Sections of fibrotic heart tissue from the UCHSC autopsy case (same sections identified in Figure 3 ) were cut using a cleaned microtome with new blade onto a pure quartz microscopy slide. This slide was placed in an X-ray fluorescence microprobe that allowed for detection of gadolinium with a sensitivity of about o1 mg g
. 15 The tissue demonstrated a strong gadolinium emissions spectra (Figure 4) , providing independent verification of gadolinium deposition within the fibrotic cardiac tissue of this patient with NSF.
DISCUSSION
In this study, we present several novel observations. First, our data, with a median time to death of just 112 days, indicates that the onset of NSF may be a harbinger of short survival. Second, we report several unique cardiac and vascular events in NSF including sudden monocular blindness secondary to posterior ischemic optic neuropathy, limb ischemia, and recurrent cardiac arrythmias. Third, we present the first evidence that NSF is associated with systemic deposition of metals including gadolinium, iron, and aluminum, with the highest quantity of gadolinium deposited in the heart, blood vessels, and skin. In a recent study, crude mortality rates were 21.2% for patients undergoing peritoneal dialysis and 24.4% for patients undergoing hemodialysis with a mean follow-up of 876 days. 16 According to the USRDS data, the mortality risk for patients on dialysis is 216 per 1000 patient-years. 17 Compared to these findings, our study indicates that mortality is higher (31.3% at 226 days) after an NSF diagnosis and may also be accelerated (median time to death of just 112 days). Specifically, accelerated cardiac and vascular disease was an important cause of death and some NSF patients died of cardiac and limb ischemia as early as one month after the onset of gadolinium-associated NSF (Figure 1) . Additionally, these patients suffered unique vascular events such as posterior ischemic optic neuropathy. Although the mechanism of these excess and unique cardiac and vascular events in NSF is unknown, our data suggest that the accumulation of metals such as gadolinium, iron, and aluminum might account for these events. In fact, the highest levels of gadolinium were found in the heart and aorta in two of our patients with myocardial fibrosis who died with myocardial ischemia and recurrent cardiac arrythmias.
Possible mechanisms for gadolinium toxicity are currently under evaluation. One such postulated mechanism, already reported by us, includes profound iron mobilization, transferrin oversaturation, and a systemic inflammatory response as a result of gadolinium exposure. 18 Iron is capable of inducing transmetallation of gadolinium chelates and this may liberate free gadolinium that is toxic. 9 Iron mobilized by the introduction of gadolinium contrast may also be directly toxic to the endothelium via oxidative stress (Fenton reaction). 12 Finally, aluminum [19] [20] [21] [22] and systemic inflammation 12 can aggravate iron-mediated injury. Thus, a combination of free gadolinium, catalytic iron, aluminum, systemic inflammation, and oxidative stress may initiate endothelial injury that evolves into a systemic fibrosing process of the tissues that is characteristic of NSF. Thus, metal deposition may contribute to as well as worsen any preexisting myocardial fibrosis and vascular calcification, 23 ventricular dysfunction, and arrhythmogenicity and high mortality in NSF. Preexisting vascular disease, 3,24 a known risk factor for NSF, may amplify these risks.
Bone aluminum accumulation is a well-known phenomenon in dialysis patients. 25 However, to our knowledge, cutaneous or vascular aluminum accumulation has never been reported. Possible mechanisms and source of excess aluminum accumulation in the tissues of NSF patients is unclear. However, we could speculate several possible mechanisms. Competition for transferrin binding between iron and aluminum could be important. 26 Unavailability of Figure 3 . The tissue demonstrates strong gadolinium emission spectra. transferrin-binding sites because of low serum transferrin levels and saturation of the remaining binding sites by mobilized iron 6 and gadolinium 27, 28 may result in excess plasma free aluminum and consequent tissue deposition. Increased dietary intake in the context of poor urinary excretion could have contributed additionally to tissue aluminum load. 29 It is feasible that some of the excess tissue aluminum along with iron participated in the transmetallation of gadolinium contrast.
Sepsis and discontinuation of dialysis are two additional factors that contributed to death in NSF-afflicted patients. Although sepsis is a common cause of death in dialysis patients, 30 gadolinium toxicity and deposition may increase the risk of sepsis through iron mobilization, 31 pro-inflammatory/immunomodulatory effects, 6 and deposition in the reticuloendothelial system. 32, 33 Our discovery of renal deposition of gadolinium is also an important finding because acute, irreversible renal failure has been observed in some patients who develop NSF after exposure to gadolinium contrast. 6 Iron is well-known to play a role in kidney injury leading to renal tubular toxicity and fibrosis. 34 This finding is of significant relevance even in patients with end-stage renal disease as loss of residual renal function significantly increases the risk of cardiovascular complications and death. 35 There are several limitations to our study including the retrospective nature of the observations and limited sample size. In addition, controls for metal analysis were obtained from patients who did not have renal insufficiency, were not exposed to gadolinium, and did not have NSF. Thus, we cannot rule out tissue accumulation of metals in patients with renal failure exposed to gadolinium but without NSF. A systemic evaluation of adjusted annual mortality rates in NSF patients could not be evaluated by this study because of a highly variable follow-up and small sample size. We observed higher tissue metal accumulation and concomitant increased cardiovascular mortality in NSF. However, our current study is not designed to address a cause-effect relationship between these two observations. Additional studies will be required to address some of these issues.
On the basis of our observations, we conclude that onset of NSF heralds a high risk of mortality from cardiac and vascular injury and fibrosis potentially related to systemic deposition of gadolinium, iron, and aluminum, demonstrable in various organs but with the highest amount of gadolinium detected in the heart and blood vessels. We speculate that metal deposition may potentially determine the severity of clinical manifestations and outcome of gadolinium contrast toxicity in patients with renal insufficiency. Finally, it is conceivable that in some patients cardiovascular manifestations of NSF may occur with variable or minimal involvement of other organs such as skin.
MATERIALS AND METHODS
Approval from the Institutional Review Board of UAMS and appropriate exemption from the Colorado Multiple Institution Review Board (COMIRB) was obtained. Thirty-four patients with NSF were identified from UAMS records and additional follow-up data could not be obtained in two of these patients. Of the remaining 32 UAMS patients diagnosed with NSF, 10 died and their data are included for further analysis. Relevant clinical history and laboratory parameters were recorded and the factors leading to death were abstracted from their medical records. Cardiovascular complications such as hypotension, arrhythmias, organ ischemic syndromes (stroke, myocardial infarction, and limb ischemia), sudden cardiac death, and CHF after NSF diagnosis were recorded. Sepsis occurring after an NSF diagnosis was also recorded. The date of gadolinium exposure, type of gadolinium contrast agent administered, and estimated renal function at the time of exposure were examined.
In two NSF patients who died at UAMS, a complete autopsy was performed after an informed consent was obtained, and the sampled organs and blood vessels were evaluated for gadolinium, iron, and aluminum quantity using ICP-MS. Autopsy data on one additional NSF patient who died at the University of Colorado Health Sciences Center (UCHSC) were also included.
De-identified paraffin-embedded blocks were submitted to investigators in Colorado for the purpose of gadolinium quantification. Quantitative measurement via ICP-MS on 30 tissue blocks was performed in a fashion similar to the previously published techniques of one of the authors (WAH). 36 Multiple 30 mM sections were cut from tissue blocks and then deparaffinized using twicedistilled xylene and ethanol. Both the autopsy tissues and control tissue biopsies were subjected to a similar de-paraffinization procedure. After drying at 105 1C until a constant dry weight was obtained, samples were placed into quartz tubes and digested with trace-metal-grade strong acids to fully oxidize all organic material. Digested samples were analyzed using ICP-MS on a PerkinElmer 6100 DRC Plus instrument (PerkinElmer Life and Analytical Sciences Inc., Waltham, MA, USA). Total gadolinium (Gd) ions were monitored at dual masses of 157. 
